3D Medicines, Inc.

3D Medicines, Inc. (1244.HK) is a commercial-stage oncology innovative drug R&D company. It has independently developed multiple differentiated innovative candidate drugs and vaccine products with global-leading or clinical value, and has established an international professional team covering R&D, production and commercialization, committed to helping cancer patients live longer and better. The company has 17 pipelines, 8 of which have entered clinical stages. Its first commercialized product, Envafolimab (the world's first subcutaneous PD-L1 single-domain antibody), has been on the market for four years and has benefited tens of thousands of patients. The company currently relies on three major self-developed platforms: an innovative In vivo CAR-T/NK technology platform, an AI+mRNA tumor vaccine 3D-preciseAG platform, and a radiopharmaceutical conjugate (RDC) R&D platform.

In December 2014, the company began drug discovery and development business through 3D Medicines Beijing (one of its principal operating subsidiaries). In February 2016, it entered into an agreement with the Alphamab Group regarding co-development and commercialization rights of Envafolimab (KN035) for oncology indications; in December 2016, it obtained IND approval for Envafolimab from China's NMPA. In 2017, it conducted first-in-human Phase I trials of Envafolimab in the United States, China and Japan. In 2018, 3D Medicines began the spin-off of its new drug business and diagnostics business, and obtained global exclusive development license for 3D185 for oncology and pulmonary fibrosis from Haihe Biopharma. In 2019, it obtained IND approval for 3D185 from the FDA and entered into a collaboration and clinical trial agreement with Alphamab Group and TRACON. In January 2020, it obtained orphan drug designation from the FDA for Envafolimab in advanced BTC. In March 2020, it entered into a tripartite cooperation agreement with Alphamab Group and Simcere Pharmaceutical Group for the production, promotion and distribution of Envafolimab in China. In October 2020, it licensed 3D1001 and 3D1002 from Haihe Biopharma for development, production and commercialization rights in China. In November 2020, it entered into a collaboration and license agreement with Aravive Inc. for 3D229. In December 2020, its BLA for Envafolimab for MSI-H/dMMR advanced solid tumors was accepted by China's NMPA, and it entered into a license agreement with SELLAS Life Sciences Group, Inc. for 3D189 and 3D059.

Leader in helping chronic cancer patients; focused on chronic cancer management and next-generation tumor immunotherapy.

• Envafolimab (KN035)

  World's first subcutaneous PD-L1 single-domain antibody; first commercialized product; on market for four years benefiting tens of thousands of patients.

• 3D189 (WT1)

  Multi-indication tumor vaccine.

• 3D1002 (EP-4)

  For tumor pain and osteoarthritis.

• 3D1001 (COX-2)

  For postoperative dental pain and tumor pain.

• 3D197

  Multi-indication tumor immunotherapy.

• 3D185 (FGFR1/2/3)

  For locally advanced or metastatic solid tumors.

• 3D011 (TKI prodrug)

  For advanced malignant solid tumors.

• 3D057

  Multi-indication.

• 3D1015

  Beta nuclide for metastatic castration-resistant prostate cancer.

• 3D1025

  Alpha nuclide for metastatic castration-resistant prostate cancer.

1. 13D Medicines-思路迪医药-专注新一代肿瘤免疫治疗3d-medicines.com
2. 23D Medicines介绍|思路迪医药优势-思路迪3D Medicines3d-medicines.com
3. 3思路迪医药发展历程-思路迪3D Medicines3d-medicines.com
4. 4核心肿瘤免疫治疗管线|注射PD-L1抗体新药-思路迪3D Medicines3d-medicines.com